Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Solutions--Er, Harvard Bioscience--Nabs Hybridization Patent

NEW YORK, Dec. 2 - A Harvard Bioscience subsidiary has won a patent for a hybridization technology that currently features in a pair of marketed devices.

 

The patent, announced last week, is the second one for this particular technology, developed by Harvard Bioscience's Genomic Solutions unit, Harvard said.

 

US Patent No. 6,432,696, entitled "Thermal and Fluidic Cycling Device for Nucleic Acid Hybridization," describes "a system that automates the processing of DNA and protein microarrays," according to Harvard Bioscience, which bought Genomic Solutions in October. The technology has already enjoyed wide market exposure: Genomic Solutions' GeneTAC Hybstation and GeneTAC Hyb4 "rely" on the technology described in both patents.

 

"Hybridization is a key step in any microarray experiment but one that can introduce unwanted variability," according to John D'Errico, Genomic Solutions' global marketing manager for genomics. The automation of the Hybstation and Hyb4 "eliminate a great deal of human error" from microarray experiments, he said. "We believe this reduces variability and gives researchers better data."

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.